Osteopororosis and reproductive health
Abstract
Osteoporosis is a prevalent issue among menopausal women; however, the number of women with risk factors across all age groups is increasing. This trend can lead to the development of osteopenia or osteoporosis at a younger age, significantly impacting women’s physical, emotional, and mental well-being. This review aims to evaluate the current literature on the prevalence of osteoporosis and its most common risk factors among women across all age groups. It serves as an updated reference for readers, helping to understand the fundamental pathophysiological mechanisms of the disease, diagnostic methods, and the role of medications and lifestyle in its prevention. Some authors suggest that the dominant mechanism of bone mass loss is slowed osteoblastic bone formation, while others highlight increased breakdown of the bone matrix as the more prominent mechanism of skeletal damage, depending on the underlying cause of osteoporosis. Increased bone fragility and a higher tendency towards pathological fractures significantly impact both the quality of life and life expectancy in women. Therefore, it is recommended that osteological screening and fracture risk assessment become a mandatory component of individualized care for women across all age groups. The focus of women’s bone health care has shifted from postmenopausal treatment to preventative care.
References
Renfro J, Brown JB. Understanding and preventing osteoporosis. AAOHN J. 1998 Apr;46(4):181–91; quiz 192–3.
Hendrickson NR, Pickhardt PJ, Del Rio AM, Rosas HG, Anderson PA. Bone Mineral Density T-Scores Derived from CT Attenuation Numbers (Hounsfield Units): Clinical Utility and Correlation with Dual-energy X-ray Absorptiometry. Iowa Orthop J. 2018;38:25–31.
Cummings SR. Bone mass and bone loss in the elderly: a special case? Int J Fertil Menopausal Stud. 1993:38 Suppl 2:92–7.
Cossio-Bolanos M, Vidal-Espinoza R, Fuentes-Lopez J, Castelli Correia de Campos LF, Andruske CL, Urra-Albornoz C, et al. Reference values for bone density and bone mineral content from 5 to 80 years old in a province of Chile. PeerJ. 2022 Mar 23;10:e13092.
Meng-Xia J, Qi Y. Primary osteoporosis in postmenopausal women.Chronic Dis Transl Med Medicine. 2015; (1):9–13.
Dimić A. Osteoporoza, Nacionalni vodič za lekare 2008. Ministarstvo zdravlja, Republička stručna komisija za izradu i implementaciju. ISBN 86-7117-114-0. [Internet]. 2008 [cited 2024 Aug 18]. Available from: https://www.zdravlje.gov.rs/view_file.php?file_id=687&cache=sr.
Levin VA, Jiang X, Kagan R. Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018;29(5):1049–55.
Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest. 2000;106(10):1203–4.
Al-Ayyadhi N, Refaat LAE, Ibrahim MM, ElGalil HMA. Screening for bone mineral density and assessment knowledge level of low peak bone risk factors and preventive practices among Kuwaiti future mothers. J Multidiscip Healthc. 2020;13:1983.
Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM. A comprehensive overview on osteoporosis and its risk factors. Ther Clin Risk Manag. 2018;14:2029–49.
Liu X, Wu Y, Bennett S, Zou J, Xu J, Zhang L. The Effects of Different Dietary Patterns on Bone Health. Nutrients. 2024;16:2289.
Rachner TD, Hofbauer LC, Göbel A, Tsourdi E. Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin. J Mol Endocrinol. 2019;62(2):R145–R154.
Khadka B, Tiwari ML, Gautam R, Timalsina B, Pathak NP, Kharel K, et al. Correlates of Biochemical Markers of Bone turnover among Post-Menopausal Women. JNMA J Nepal Med Assoc. 2018;56(212):754–8.
Chew CK, Clarke BL. Causes of low pick bone mass in women. Maturitas. 2018;111:61–8.
Salari N, Ghasemi H, Loghman M, Behzadi MH, Rabieenia E, Shohaimi S, Mohammadi M. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021;16:1983–91.
Kanis, J. Assessment of Osteoporosis at the Primary Health Care Level. Technical Report, World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield [Internet]. 2007 [cited 2024 Aug 12]. Available from: https://frax.shef.ac.uk/
FRAX/pdfs/WHO_Technical_Report.pdf.
Van Dort MJ, Driessen JHM, Geusens P, Romme EAPM, Smeenk FWJM, Wouters EFM, van den Bergh JPW. Vertebral bone attenuation in Hounsfield Units and prevalent vertebral fractures are associated with the short-term risk of vertebral fractures in current and ex-smokers with and without COPD: a 3-year chest CT follow-up study. Osteoporos Int. 2019;30(8):1561–71.
Thomasius F, Hadji P. Influence of hormone or hormone replacement therapy on bone healing. Unfallchirurg. 2019;122(7):512–7.
Ranson WA, Patterson DC, Colvin AC. Female athlete triad: Past, present, and future directions. Ann Joint. 2018;3:4.
Siddiqui JA, Partridge NC. Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement. Physiology (Bethesda). 2016 May;31(3):233–45.
Samwald U, Dovjak P, Azizi-Semrad U, Kerschan-Schindl K, Pietschmann P. Osteoporosis: Pathophysiology and therapeutic options. EXCLI J. 2020;19:1017–37.
Longo N, editor. Harison’s principles of internal medicine. 18th edition. Mc Graw Hill; 2012.
Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008 May 15;473(2):139–46.
Chambers TJ, Athanasou NA, Fuller K. Effect of parathyroid hormone and calcitonin on the cytoplasmic spreading of isolated osteoclasts. J Endocrinol. 1984;102(3):281–6.
Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simões MJ, Cerri PS. Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells. Biomed Res Int. 2015;2015:421746.
Silva de Sá MF. Premature Ovarian Insufficiency and Bone Health Care: A Concern of the Gynecologist. Rev Bras Ginecol Obstet. 2018;40(6):305–308.
Bikle DD. Vitamin D and bone. Curr Osteoporos Rep. 2012 Jun;10(2):151–9.
Crooks E, Bendall S. Parathyroid hormone and vitamin D: from bench to bedside. J Orthop Trauma. 2021;35(5):267–273.
Notelovitz M. Androgen effects on bone and muscle. Fertil Steril. 2002;77 (4):34–41.
Almeida M, Laurent MR, Dubois V, Claessens F, O'Brien CA, Bouillon R, et al. Estrogens and Androgens in Skeletal Physiology and Pathophysiology. Physiol Rev. 2017 Jan;97(1):135–87.
Guder C, Gravius S, Burger C, Wirtz DC, Schildberg FA. Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System. Front Immunol. 2020;11:58.
Inchingolo F, Inchingolo AM, Piras F, Ferrante L, Mancini A, Palermo A, et al. The interaction between gut microbiome and bone health. Curr Opin Endocrinol Diabetes Obes. 2024;31(3):122–30.
Tu Ye, Yang R, Xu X, Zhou X. The microbiota-gut-bone axis and bone health. J Leukoc Biol. 2021;110:525–37.
Khosla S, Farr JN, Monroe DG. Cellular senescence and the skeleton: pathophysiology and therapeutic implications. J Clin Invest. 2022;132(3):154888.
National osteoporosis foundation. Clinician’s guide to prevention and treatment of osteoporosis [Internet]. 2008 [cited 2024 Nov 25]. Available from: https://www.natap.org/
/HIV/NOF_Clinicians_Guide-1.pdf.
Löffler MT, Jacob A, Valentinitsch A, Rienmüller A, Zimmer C, Ryang YM, et al. Improved prediction of incident vertebral fractures using opportunistic QCT compared to DXA. Eur Radiol. 2019;29(9):4980–9.
Gutierrez-Buey G, Restituto P, Botella S, Monreal I, Colina I, Rodríguez-Fraile M, et al. Trabecular bone score and bone remodelling markers identify perimenopausal women at high risk of bone loss. Clin Endocrinol. 2019;91(3):391–9.
Glover SJ, Gall M, Schoenborn-Kellenberger O, Wagener M, Garnero P, Boonen S, et al. Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States. J Bone Miner Res. 2009;24:389–97.
Hu W, Zeng H, Jin-Wei F, Wen-Zhen W, Chun Z, Hao Y, et al. Establishing Reference Intervals for Bone Turnover Markers in the Healthy Shanghai Population and the Relationship with Bone Mineral Density in Postmenopausal Women. Int J Endocrinol. 2013;2013:513925.
Saad MA, Aboelwafa RA, Elsayed EH. Could procollagen type I N-terminal propeptide (PINP) and bone alkaline phosphatase (B-ALP) be valid alternative diagnostic markers to dual X-ray absorptiometry (DEXA) in elderly females with osteoporosis? An Egyptian radiological and laboratory monocentric study. Egypt Rheumatol Rehabil. 2021;48:20.
Mobasseri M, Tarverdizadeh N, Mirghafourvand M, Salehi-Pourmehr H, Ostadrahimi A, Farshbaf-Khalili A. The role of bone turnover markers in screening low bone mineral density and their relationship with fracture risk in the postmenopausal period. J Res Med Sci. 2023;28:54.
Hlaing TT, Compston JE. Biochemical markers of bone turnover – uses and limitations. Ann Clin Biochem. 2014;52:189–202.
Liu Z, Wang S, Dong D, Wei J, Fang C, Zhou X, et al. The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges. Theranostics. 2019;9:1303–22.
Savage RH, van Assen M, Martin SS, Sahbaee P, Griffith LP, Giovagnoli D, et al. Utilizing Artificial Intelligence to Determine Bone Mineral Density Via Chest Computed Tomography. J Thorac Imaging. 2020;35(Suppl. S1):S35–S39.
Ong W, Liu RW, Makmur A, Low XZ, Sng WJ, Tan JH, et al. Artificial Intelligence Applications for Osteoporosis Classification Using Computed Tomography. Bioengineering (Basel). 2023 Nov 27;10(12):1364.
Spencer H. Osteoporosis: Goals of therapy. Hosp Pract. 1982;17(3):131–43.
LeBoff MS, Greenspan SL, Insogna KL, Lewiecki KL, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049–102.
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478–87.
Mucke T, Krestan CR, Mitchell DA, Kirschke JS, Wutzl A. Bisphosphonate and medication-related osteonecrosis of the jaw: A review. Semin Musculoskelet Radiol. 2016;20:305–14.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41.
Chen Y, Zhu LL, Zhou Q. Effects of drug pharmacokinetic/pharmacodynamic properties, characteristics of medication use, and relevant pharmacological interventions on fall risk in elderly patients. Ther Clin Risk Manag. 2014;10:437–48.
Eastell R, Rosen CJ, Black D, Cheung A, Hassan M, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019 May 1;104(5):1595–622.
